Actively Recruiting
Postoperative Analgesia in Patients Undergoing Open Upper Abdominal Surgeries: External Oblique Intercostal Plane Block vs. Quadratus Lumborum Block
Led by Cairo University · Updated on 2025-08-17
80
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Open upper abdominal surgeries with subcostal incisions are a cause of severe pain and can lead to pulmonary and cardiac complications, detrimental physiological effects, and may also have psychological, economic, and social adverse effects if inadequately treated. Effective pain control can avoid these complications and contribute to several clinically valuable outcomes, including earlier patient mobilization and quicker recovery, which can result in a shortened hospital stay and reduced costs. Opioids are the gold standard in postoperative pain control. however, it increases the incidence of opioid related adverse events such as respiratory depression, dizziness, nausea, vomiting and constipation. Regional analgesia plays an important role in perioperative multimodal analgesic regimens for major abdominal surgeries. The ultrasound-guided technique provides several options for relieving postoperative pain. The aim of this study is to compare the efficacy and safety of ultrasound guided external oblique intercostal plane block versus quadratus lumborum in patients undergoing open upper abdominal surgeries.
CONDITIONS
Official Title
Postoperative Analgesia in Patients Undergoing Open Upper Abdominal Surgeries: External Oblique Intercostal Plane Block vs. Quadratus Lumborum Block
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of any gender
- Aged 18 to 60 years
- ASA physical status I to III
- Scheduled for elective open upper abdominal surgeries such as open nephrectomy, open cholecystectomy, liver resection
- Body mass index between 18.5 and 35 kg/m2
You will not qualify if you...
- Uncooperative patients or those who refuse to sign consent for regional block
- Known coagulation defects (INR > 1.5) or platelet count below 100,000
- Known allergy to bupivacaine or any used drugs
- Hepatic impairment including Child-Pugh class B or C, AST/ALT more than 3 times normal, or total bilirubin over 2 mg/dL
- Renal impairment with chronic kidney disease stage 4 or 5 (eGFR < 30 mL/min/1.73 m2) or on dialysis
- Pre-existing muscle disorders causing weakness or elevated creatine kinase
- Pre-existing nerve disorders such as peripheral or central neuropathy
- Chronic pain syndromes lasting more than 3 months, including fibromyalgia or complex regional pain syndrome
- Sepsis at the injection site
- History of long-acting opioid or steroid use before surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cairo university hospitals
Cairo, Egypt
Actively Recruiting
Research Team
N
Nesrine Elrefai, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here